BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12837690)

  • 21. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
    Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiT family translocation renal cell carcinoma.
    Argani P
    Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development.
    Steingrimsson E; Tessarollo L; Pathak B; Hou L; Arnheiter H; Copeland NG; Jenkins NA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4477-82. PubMed ID: 11930005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors.
    Rehli M; Lichanska A; Cassady AI; Ostrowski MC; Hume DA
    J Immunol; 1999 Feb; 162(3):1559-65. PubMed ID: 9973413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiT/TFE Family Renal Cell Carcinoma.
    Tang J; Baba M
    Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature.
    Peckova K; Vanecek T; Martinek P; Spagnolo D; Kuroda N; Brunelli M; Vranic S; Djuricic S; Rotterova P; Daum O; Kokoskova B; Vesela P; Pivovarcikova K; Bauleth K; Dubova M; Kalusova K; Hora M; Michal M; Hes O
    Ann Diagn Pathol; 2014 Dec; 18(6):351-7. PubMed ID: 25438924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
    Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
    Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TFEC, a basic helix-loop-helix protein, forms heterodimers with TFE3 and inhibits TFE3-dependent transcription activation.
    Zhao GQ; Zhao Q; Zhou X; Mattei MG; de Crombrugghe B
    Mol Cell Biol; 1993 Aug; 13(8):4505-12. PubMed ID: 8336698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
    Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
    Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of renal carcinoma with t(6;11)(p21;q12) with focus on clinical and pathobiological aspects.
    Kuroda N; Tanaka A; Sasaki N; Ishihara A; Matsuura K; Moriyama M; Nagashima Y; Inoue K; Petersson F; Martignoni G; Michal M; Hes O
    Histol Histopathol; 2013 Jun; 28(6):685-90. PubMed ID: 23426439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
    Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
    Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
    Medendorp K; van Groningen JJ; Vreede L; Hetterschijt L; Brugmans L; van den Hurk WH; van Kessel AG
    Exp Cell Res; 2009 Aug; 315(14):2399-409. PubMed ID: 19422821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.
    Clark J; Lu YJ; Sidhar SK; Parker C; Gill S; Smedley D; Hamoudi R; Linehan WM; Shipley J; Cooper CS
    Oncogene; 1997 Oct; 15(18):2233-9. PubMed ID: 9393982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas.
    Weterman MA; van Groningen JJ; Tertoolen L; van Kessel AG
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13808-13. PubMed ID: 11717438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TFEB has DNA-binding and oligomerization properties of a unique helix-loop-helix/leucine-zipper family.
    Fisher DE; Carr CS; Parent LA; Sharp PA
    Genes Dev; 1991 Dec; 5(12A):2342-52. PubMed ID: 1748288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.
    Rao Q; Zhang XM; Tu P; Xia QY; Shen Q; Zhou XJ; Shi QL
    Int J Clin Exp Pathol; 2013; 6(7):1452-7. PubMed ID: 23826432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
    Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
    Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
    Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.